A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC
A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic Renal Cell Cancer
Sponsor: Sunshine Lake Pharma Co., Ltd.
Terminated
The effect of CT053PTSA in preciously treated patients with advanced and metastatic RCC is not as good as pre-expected
Other terminated trials from Sunshine Lake Pharma Co., Ltd.
- Hepatitis B, Chronic · Phase PHASE1/PHASE2 · Mar 2023
- Pancreatic Cancer · Phase PHASE1 · Sep 2021
- Acute Myeloid Leukemia (AML) · Phase PHASE1 · Aug 2019
More terminations from Sunshine Lake Pharma Co., Ltd.
A PHASE1/PHASE2 clinical study on Renal Cell Cancer Metastatic, this trial is terminated or withdrawn. The trial is conducted by Sunshine Lake Pharma Co., Ltd. and has accumulated 6 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Apr 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 1 earlier version
-
Apr 2019 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sunshine Lake Pharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .